{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:14Z","timestamp":1787587214889,"version":"build-2736575974"},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1248\/bpb.b19-00652","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T22:05:18Z","timestamp":1568757918000},"page":"2089-2094","source":"Crossref","is-referenced-by-count":24,"title":["Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients"],"prefix":"10.1248","volume":"42","author":[{"given":"Tomohiro","family":"Izumisawa","sequence":"first","affiliation":[{"name":"Laboratory of Physiological Chemistry, Institute of Medicinal Chemistry, Hoshi University"},{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Soma","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Imai","sequence":"additional","affiliation":[{"name":"Laboratory of Physiological Chemistry, Institute of Medicinal Chemistry, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Wakui","sequence":"additional","affiliation":[{"name":"Division of Applied Pharmaceutical Education and Research, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Jikei University Kashiwa Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Horino","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Control, Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Laboratory of Physiological Chemistry, Institute of Medicinal Chemistry, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Sakai C, Satoh Y, Ohkusu K, Kumagai K, Ishii A. Outbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization among patients with neoplastic disease: a clinico-epidemiological study of 11 cases. <i>Kansenshogaku Zasshi<\/i>, <b>75<\/b>, 940\u2013945 (2001)."},{"key":"2","unstructured":"2) Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. <i>Int. J. Antimicrob. Agents<\/i>, <b>37<\/b>, 95\u2013101 (2011)."},{"key":"3","unstructured":"3) Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant <i>Staphylococcus aureus<\/i> bacteremia: support for consensus guidelines suggested targets. <i>Clin. Infect. Dis.<\/i>, <b>52<\/b>, 975\u2013981 (2011)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients. <i>Clin. Infect. Dis.<\/i>, <b>49<\/b>, 507\u2013514 (2009).","DOI":"10.1086\/600884"},{"key":"5","unstructured":"5) Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can\u2019t get there from here. <i>Clin. Infect. Dis.<\/i>, <b>52<\/b>, 969\u2013974 (2011)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections in adults and children. <i>Clin. Infect. Dis.<\/i>, <b>52<\/b>, e18\u2013e55 (2011).","DOI":"10.1093\/cid\/ciq146"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant <i>Staphylococcus aureus<\/i> with reduced vancomycin susceptibility. <i>Clin. Infect. Dis.<\/i>, <b>38<\/b>, 521\u2013528 (2004).","DOI":"10.1086\/381202"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. <i>Clin. Infect. Dis.<\/i>, <b>42<\/b> (Suppl. 1), S35\u2013S39 (2006).","DOI":"10.1086\/491712"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. <i>Antimicrob. Agents Chemother.<\/i>, <b>49<\/b>, 4934\u20134941 (2005).","DOI":"10.1128\/AAC.49.12.4934-4941.2005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Aldaz A, Ortega A, Idoate A, Giraldez J, Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. <i>Ther. Drug Monit.<\/i>, <b>22<\/b>, 250\u2013257 (2000).","DOI":"10.1097\/00007691-200006000-00004"},{"key":"11","unstructured":"11) Fern\u00e1ndez de Gatta MM, Fruns I, Hernandez JM, Caballero D, San Miguel JF, Martinez Lanao J, Dominguez-Gil Hurle A. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. <i>Clin. Pharm.<\/i>, <b>12<\/b>, 515\u2013520 (1993)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. <i>Ther. Drug Monit.<\/i>, <b>20<\/b>, 139\u2013148 (1998).","DOI":"10.1097\/00007691-199804000-00003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Jelliffe RW, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Barbaut X, Maire P. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new \u2018multiple model\u2019 dosage design, bayesian feedback and individualised target goals. <i>Clin. Pharmacokinet.<\/i>, <b>34<\/b>, 57\u201377 (1998).","DOI":"10.2165\/00003088-199834010-00003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto K, Tsuji A. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. <i>Biol. Pharm. Bull.<\/i>, <b>25<\/b>, 1333\u20131338 (2002).","DOI":"10.1248\/bpb.25.1333"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ohnishi A, Yano Y, Shimamura K, Oguma T. Evaluation of Bayesian predictability of vancomycin concentration in patients with various degrees of renal function. <i>Biol. Pharm. Bull.<\/i>, <b>24<\/b>, 1446\u20131450 (2001).","DOI":"10.1248\/bpb.24.1446"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. <i>Int. J. Antimicrob. Agents<\/i>, <b>39<\/b>, 420\u2013423 (2012).","DOI":"10.1016\/j.ijantimicag.2011.12.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. <i>Intensive Care Med.<\/i>, <b>39<\/b>, 1247\u20131252 (2013).","DOI":"10.1007\/s00134-013-2909-9"},{"key":"18","unstructured":"18) Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M. Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. <i>Crit. Care Med.<\/i>, <b>8<\/b>, 68\u201372 (1980)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented creatinine clearance in traumatic brain injury. <i>Anesth. Analg.<\/i>, <b>111<\/b>, 1505\u20131510 (2010).","DOI":"10.1213\/ANE.0b013e3181f7107d"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Conil JM, Georges B, Fourcade O, Seguin T, Lavit M, Samii K, Houin G, Tack I, Saivin S. Assessment of renal function in clinical practice at the bedside of burn patients. <i>Br. J. Clin. Pharmacol.<\/i>, <b>63<\/b>, 583\u2013594 (2007).","DOI":"10.1111\/j.1365-2125.2006.02807.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. <i>Nat. Rev. Nephrol.<\/i>, <b>7<\/b>, 539\u2013543 (2011).","DOI":"10.1038\/nrneph.2011.92"},{"key":"22","unstructured":"22) Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. <i>Chest<\/i>, <b>142<\/b>, 30\u201339 (2012)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. <i>Crit. Care<\/i>, <b>15<\/b>, R139 (2011).","DOI":"10.1186\/cc10262"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. <i>Kidney Int.<\/i>, <b>77<\/b>, 760\u2013764 (2010).","DOI":"10.1038\/ki.2010.35"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. <i>Pediatr. Infect. Dis. J.<\/i>, <b>13<\/b>, 969\u2013974 (1994).","DOI":"10.1097\/00006454-199411000-00007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. <i>Pediatr. Infect. Dis. J.<\/i>, <b>14<\/b>, 667\u2013672 (1995).","DOI":"10.1097\/00006454-199508000-00004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Krivoy N, Peleg S, Postovsky S, Arush MWB. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. <i>Pediatr. Hematol. Oncol.<\/i>, <b>15<\/b>, 333\u2013338 (1998).","DOI":"10.3109\/08880019809014017"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Le Normand Y, Milpied N, Kergueris MF, Harousseau JL. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. <i>Int. J. Biomed. Comput.<\/i>, <b>36<\/b>, 121\u2013125 (1994).","DOI":"10.1016\/0020-7101(94)90102-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sadoh S, Tsuji Y, Tsukamoto K. Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies. <i>Yakugaku Zasshi<\/i>, <b>130<\/b>, 69\u201373 (2010).","DOI":"10.1248\/yakushi.130.69"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Omote S, Yano Y, Hashida T, Masuda S, Yano I, Katsura T, Inui K. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. <i>Biol. Pharm. Bull.<\/i>, <b>32<\/b>, 99\u2013104 (2009).","DOI":"10.1248\/bpb.32.99"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <i>Nephron<\/i>, <b>16<\/b>, 31\u201341 (1976).","DOI":"10.1159\/000180580"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. <i>J. Pharmacokinet. Biopharm.<\/i>, <b>9<\/b>, 503\u2013512 (1981).","DOI":"10.1007\/BF01060893"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with Gram-positive infections and the influence of infectious disease type. <i>J. Clin. Pharm. Ther.<\/i>, <b>34<\/b>, 473\u2013483 (2009).","DOI":"10.1111\/j.1365-2710.2008.01016.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M. Glomerular hyperfiltration and albuminuria in critically ill patients. <i>Anaesth. Intensive Care<\/i>, <b>36<\/b>, 674\u2013680 (2008).","DOI":"10.1177\/0310057X0803600507"},{"key":"35","unstructured":"35) Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. <i>Crit. Care Med.<\/i>, <b>42<\/b>, 520\u2013527 (2014)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. <i>Antimicrob. Agents Chemother.<\/i>, <b>37<\/b>, 1132\u20131136 (1993).","DOI":"10.1128\/AAC.37.5.1132"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/12\/42_b19-00652\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T03:24:32Z","timestamp":1575689072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/12\/42_b19-00652\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00652","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}